ID: ALA5273338

Max Phase: Preclinical

Molecular Formula: C19H13NO

Molecular Weight: 271.32

Associated Items:

Representations

Canonical SMILES:  O=C(c1ccccc1)c1cc2c(ccc3ccccc32)[nH]1

Standard InChI:  InChI=1S/C19H13NO/c21-19(14-7-2-1-3-8-14)18-12-16-15-9-5-4-6-13(15)10-11-17(16)20-18/h1-12,20H

Standard InChI Key:  RGRNKAPBCROJME-UHFFFAOYSA-N

Associated Targets(Human)

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 1469 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 271.32Molecular Weight (Monoisotopic): 271.0997AlogP: 4.55#Rotatable Bonds: 2
Polar Surface Area: 32.86Molecular Species: NEUTRALHBA: 1HBD: 1
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.34CX Basic pKa: CX LogP: 4.44CX LogD: 4.44
Aromatic Rings: 4Heavy Atoms: 21QED Weighted: 0.53Np Likeness Score: -0.34

References

1. Wang Y, Qu C, Liu T, Wang C..  (2020)  PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships.,  203  [PMID:32679452] [10.1016/j.ejmech.2020.112612]

Source